- Home
- ANNX
ANNX
Annexon Inc.
as 11-22-2024 4:00pm EST
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 668.8M | IPO Year: | 2020 |
| Target Price: | $15.80 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.27 - $8.40 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Annexon Inc. (ANNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Oct 15 '24 | Sell | $7.41 | 5,408 | $40,073.28 | 71,365 | |
| Carson William H. | ANNX | Director | Oct 1 '24 | Buy | $5.97 | 3,200 | $19,104.00 | 22,400 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Sep 19 '24 | Sell | $7.10 | 4,500 | $31,950.00 | 71,365 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Sep 12 '24 | Sell | $6.16 | 5,500 | $33,880.00 | 71,365 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Sep 5 '24 | Sell | $5.64 | 5,500 | $31,020.00 | 71,365 | |
| Carson William H. | ANNX | Director | Sep 3 '24 | Buy | $5.48 | 3,200 | $17,536.00 | 22,400 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Aug 29 '24 | Sell | $5.95 | 5,500 | $32,725.00 | 71,365 |
Latest Annexon Inc. News
ANNX Breaking Stock News: Dive into ANNX Ticker-Specific Updates for Smart Investing
Pharma Voice
6 days ago
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
GlobeNewswire
9 days ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
10 days ago
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
GlobeNewswire
11 days ago
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
GlobeNewswire
a month ago
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Simply Wall St.
a month ago
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
GlobeNewswire
a month ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Compare ANNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANNX Annexon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.